Patients with Obesity and a History of Metformin Treatment Have Lower Influenza Mortality: A Retrospective Cohort Study
- PMID: 35215211
- PMCID: PMC8876732
- DOI: 10.3390/pathogens11020270
Patients with Obesity and a History of Metformin Treatment Have Lower Influenza Mortality: A Retrospective Cohort Study
Abstract
Background: Obesity is a risk factor for the development of influenza by leading to a chronic inflammatory state and T-cell dysfunction. Based upon preclinical research, metformin has influenza activity by restoring T-cell function and improving the immune response.
Objective: We aimed to evaluate the potential drug repurposing of metformin for the management of influenza among patients with obesity utilizing national claims data in an electronic health record database.
Methods: The VA Informatics and Computing Infrastructure (VINCI) was utilized to obtain individual-level information on demographics, administrative claims, and pharmacy dispensation. A cohort was created among individuals with laboratory confirmed diagnosis of influenza with a diagnosis of fever, cough, influenza, or acute upper respiratory infection in an outpatient setting. The study outcome was death after diagnosis of influenza. Cohorts were formed using diabetes status and metformin exposure prior to a positive influenza diagnosis. Hazard ratios for mortality were estimated using a cox proportional hazards model adjusting for baseline covariates and a sub-analysis was conducted utilizing propensity score matching. A greedy nearest neighbor algorithm was utilized to match 1 to 1 non-metformin diabetic controls and non-diabetic controls to diabetic patients receiving metformin.
Results: A total of 3551 patients met the inclusion criteria and were evaluated in our study. The cohorts consisted of 1461 patients in the non-diabetic cohort, 1597 patients in the diabetic / metformin cohort, and 493 patients in the diabetic no metformin cohort. Compared to non-diabetic patients, diabetic patients with metformin had a lower rate of death (aHR 0.78, 95% CI 0.609-0.999). There was not a statistical difference between the non-diabetic patients and the diabetic patients without metformin (aHR 1.046, 95% CI 0.781-1.400). The propensity score matched cohorts revealed consistent results with the primary analysis.
Conclusion: Our results demonstrated patients with obesity and a history of metformin treatment have lower influenza mortality.
Keywords: T-cell restoration; drug repurposing; influenza; metformin; obesity.
Conflict of interest statement
S.S.S., T.H.C, and J.M. receive support from the National Institutes of Health (NIH) grant R01DA054992 and the South Carolina Center for Rural and Primary Healthcare unrelated to this work. S.S.S. has received research grants from Boehringer Ingelheim, Gilead Sciences, Alexion Pharmaceuticals, and United Therapeutics unrelated to this work. The other authors declare no competing interests.
Similar articles
-
Drug repurposing of dextromethorphan as a cellular target for the management of influenza.Pharmacotherapy. 2021 Oct;41(10):796-803. doi: 10.1002/phar.2618. Epub 2021 Sep 18. Pharmacotherapy. 2021. PMID: 34428315
-
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.Lancet Healthy Longev. 2021 Jan;2(1):e34-e41. doi: 10.1016/S2666-7568(20)30033-7. Epub 2020 Dec 3. Lancet Healthy Longev. 2021. PMID: 33521772 Free PMC article.
-
Association between metformin and abdominal aortic aneurysm in diabetic and non-diabetic US veterans.J Investig Med. 2020 Jun;68(5):1015-1018. doi: 10.1136/jim-2019-001177. Epub 2020 Apr 8. J Investig Med. 2020. PMID: 32273298
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Diverse Applications of the Anti-Diabetic Drug Metformin in Treating Human Disease.Pharmaceuticals (Basel). 2024 Nov 27;17(12):1601. doi: 10.3390/ph17121601. Pharmaceuticals (Basel). 2024. PMID: 39770443 Free PMC article. Review.
Cited by
-
Metformin in Antiviral Therapy: Evidence and Perspectives.Viruses. 2024 Dec 18;16(12):1938. doi: 10.3390/v16121938. Viruses. 2024. PMID: 39772244 Free PMC article. Review.
-
Serum Bilirubin Levels and Risk of Venous Thromboembolism among Influenza Patients: A Cohort Study.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241275138. doi: 10.1177/10760296241275138. Clin Appl Thromb Hemost. 2024. PMID: 39215507 Free PMC article.
-
Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults.Front Aging. 2023 Oct 11;4:1272336. doi: 10.3389/fragi.2023.1272336. eCollection 2023. Front Aging. 2023. PMID: 37886013 Free PMC article. Review.
-
Metformin for Treatment of Acute COVID-19: Systematic Review of Clinical Trial Data Against SARS-CoV-2.Diabetes Care. 2023 Jul 1;46(7):1432-1442. doi: 10.2337/dc22-2539. Diabetes Care. 2023. PMID: 37339345 Free PMC article.
-
Metformin: update on mechanisms of action and repurposing potential.Nat Rev Endocrinol. 2023 Aug;19(8):460-476. doi: 10.1038/s41574-023-00833-4. Epub 2023 May 2. Nat Rev Endocrinol. 2023. PMID: 37130947 Free PMC article. Review.
References
-
- World Health Organization Global influenza strategy 2019–2030. 2019. [(accessed on 26 January 2022)]. Available online: https://apps.who.int/iris/handle/10665/311184.
-
- CDC Pandemic Basics. [(accessed on 26 January 2022)];2017 Available online: https://www.cdc.gov/flu/pandemic-resources/basics/faq.html.
-
- Morgan O.W., Bramley A., Fowlkes A., Freedman D.S., Taylor T.H., Gargiullo P., Belay B., Jain S., Cox C., Kamimoto L., et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS ONE. 2010;5:e9694. doi: 10.1371/journal.pone.0009694. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous